Zobrazeno 1 - 10
of 735
pro vyhledávání: '"Patrick, Schöffski"'
Autor:
Tom Vandaele, Jan Van Slambrouck, Patrick Schöffski, Herlinde Dumez, Birgit Weynand, Raf Sciot, Annalisa Barbarossa, An-Lies Provoost, Kristof Van de Voorde, Yves Debaveye, Sofian Bouneb, Philippe Nafteux, Laurens J. Ceulemans
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Pleural neoplasms are rare and can be subdivided into pleural metastasis and primary pleural neoplasms. Non-mesothelioma primary pleural neoplasms are a diverse group of extremely rare pathologies. Case presentation In this case s
Externí odkaz:
https://doaj.org/article/3b9699ca8efa44beb4a7a5afbe584a46
Autor:
Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimu
Externí odkaz:
https://doaj.org/article/be397a2c9d104c41b010a59bc9500941
Autor:
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTIeramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination tr
Externí odkaz:
https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a
Autor:
Lore De Cock, Flavia Paternostro, Ulla Vanleeuw, Karo Wyns, Annouschka Laenen, Che-Jui Lee, Raf Sciot, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Translational Oncology, Vol 48, Iss , Pp 102057- (2024)
Background: Synovial sarcoma (SynSa) is one of the most common translocation-related soft tissue sarcomas. Patients with metastatic SynSa have limited treatment options and a very poor prognosis. Several novel experimental therapies are currently bei
Externí odkaz:
https://doaj.org/article/1849db8fb1904ffe95310ec132df2b55
Autor:
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundNintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC).DesignEORTC-1209 (NCT01788
Externí odkaz:
https://doaj.org/article/6cb94876a3044358996b174c5e0cfcd4
Autor:
Rafael Zago Baltazar, Sofie Claerhout, Sara Vander Borght, Lien Spans, Raphael Sciot, Patrick Schöffski, Daphne Hompes, Friedl Sinnaeve, Hazem Wafa, Marleen Renard, Mari FCM van den Hout, Astrid Vernemmen, Louis Libbrecht, An‐Katrien De Roo, Filomena Mazzeo, Cédric van Marcke, Karen Deraedt, Claire Bourgain, Isabelle Vanden Bempt
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract The identification of gene fusions has become an integral part of soft tissue and bone tumour diagnosis. We investigated the added value of targeted RNA‐based sequencing (targeted RNA‐seq, Archer FusionPlex) to our current molecular diag
Externí odkaz:
https://doaj.org/article/a4e531c2073947398417e6e0aa6c457f
Autor:
Patrick Schöffski, Suzanne George, Michael C. Heinrich, John R. Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ f
Externí odkaz:
https://doaj.org/article/9bb5658e944d433ba93df74a037e4505
Autor:
Szymon Macioszek, Danuta Dudzik, Rafał Bartoszewski, Tomasz Stokowy, Diether Lambrechts, Bram Boeckx, Agnieszka Wozniak, Patrick Schöffski, Michał J. Markuszewski
Publikováno v:
Translational Oncology, Vol 30, Iss , Pp 101632- (2023)
Background: Although imatinib is a well-established first-line drug for treating a vast majority of gastrointestinal stromal tumours (GIST), GISTs acquire secondary resistance during therapy. Multi-omics approaches provide an integrated perspective t
Externí odkaz:
https://doaj.org/article/45e412c3a749489d854a7e0c278adf19
Autor:
Maria A. Pantaleo, Michael C. Heinrich, Antoine Italiano, Claudia Valverde, Patrick Schöffski, Giovanni Grignani, Anna K. L. Reyners, Sebastian Bauer, Peter Reichardt, Daniel Stark, Ghimja Berhanu, Ulrike Brandt, Tommaso Stefanelli, Hans Gelderblom
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidy
Externí odkaz:
https://doaj.org/article/2f1e77cece464909a2d9a3ecf8c75f78
Autor:
Lisa Kinget, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, Benoit Beuselinck
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3227-3239 (2021)
In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline al
Externí odkaz:
https://doaj.org/article/7a39b9d2c6fd430fa1ce2c4042e5f079